Phase 2 Study Evaluates Serplulimab Plus HLX04 as First-Line Treatment for Advanced Hepatocellular Carcinoma
An open-label, multicenter phase 2 study (NCT03973112) conducted in China aimed to investigate the safety and initial effectiveness of serplulimab...